ABSTRACT
INTRODUCTION
A screening protocol that is rapid and efficient for detection of specific monoclonal antibodies (MAbs) facilitates projects involving generation of hybridomas. In particular, the generation of MAbs that can detect low-abundance cytoplasmic proteins in a wide range of applications requires a suitable screening procedure. Current hybridoma screening methods such as antibody capture assays, nitrocellulose dot blots (9) , solid-phase radioimmunoassay (2) or enzyme-linked immunosorbent assay (ELISA) (5) are not optimal when it is important that the resulting antibodies be used in additional applications, such as Western blotting and immunohistochemistry. Modified methods of antigen capture on the cell surface, using fluorochrome-or enzyme-labeled reagents (12, 15, 23, 24) are tedious and time-consuming to perform. Screening by cell surface immunofluorescence staining, although rapid and highly sensitive (14) , is limited to cell surface antigens. Assays in which hybridoma tissue culture supernatants are used either to block a reaction or to deplete an essential component from a reaction mixture are difficult to perform (8) . Moreover, there is no in vitro biochemical assay for many proteins.
We were interested in generating antibodies to Bim, a cytoplasmic Bcl-2-related protein that promotes apoptosis (16) . There are at least three spliced forms of Bim: Bim S (short), Bim L (long) and Bim EL (extra long). All contain a BH3 ( B cl-2 Homology) domain (3) , which is essential for Bim to promote cell death and for binding to the anti-apoptotic Bcl-2 family members. To our knowledge, no other region or protein with resemblance to Bcl-2 family members has been identified so far. Northern blot analysis showed that bim mRNA was expressed at low levels in many cell lines but was not present in the myeloid line FDC-P1 (16) . The proapoptotic activity of Bim and the finding that bimmRNA levels are low in normal tissues made it clear that specific MAbs had to be generated to determine the tissue distribution of Bim and its subcellular localization at physiological concentrations. This information is essential to understanding the function of Bim in the molecular control of apoptosis and its role in both normal physiology and disease states.
We designed a tailor-made strategy to identify hybridomas that produce specific antibodies to Bim. We have also adapted this screening procedure to another intracellular protein (Bcl-w) regulating apoptosis (7), indicating that it may be of general applicability.
MATERIALS AND METHODS

Immunization
Wistar rats were immunized by injection of 100 µ g of purified glutathione-S-transferase (GST)-Bim L fusion protein, purified on a Glutathione Sepharose ® Affinity Matrix (Amersham Pharmacia Biotech, Uppsala, Sweden). For the first immunization, the protein was dissolved in complete Freund's adjuvant (Difco Laboratories, Detroit, MI, USA) and injected subcutaneously. Two subsequent boosts of the immunogen resuspended in incomplete Freund's adjuvant (Difco Laboratories) were injected subcutaneously 3 and 6 weeks after the initial injection. Four weeks later, a final boost was given followed by spleen cell fusion three days later.
Cell Fusion and Hybridoma Culture
Rat spleen cells were fused according to published procedures (6) with Sp2/0 mouse myeloma cells (18) at an approximate ratio of 2:1 to 4:1, using polyethylene glycol 1500 (Boehringer Mannheim, Mannheim, Germany). After fusion, the cells were resuspended in Dulbecco's modified Eagle medium (DMEM) containing 15% MultiSer fetal calf serum (FCS) (Batch No. 31104149; Trace Bioscience, Sydney, NSW, Australia), 5 mM hypoxanthine, 0.02 mM aminopterin and 0.8 mM thymidine (HAT; Boehringer Mannheim), with Interleukin (IL)-6 and plated into Falcon ® flat-bottom, 96-well plates (Becton Dickinson Labware, Bedford, MA, USA). The source of IL-6 was supernatant from X63/0 hybridoma cells stably transfected with an IL-6 expression construct (11) . The titer of IL-6 in the supernatant was determined by stimulation of the IL-6-dependent cell line 7TD1 (22) . IL-6 was used in the fusion medium at a concentration that permitted maximal proliferation of 7TD1 cells. Fresh tissue culture medium was added to the hybridoma cells on day 7 after fusion, and supernatants were harvested for analysis on days 9-11, depending on the rate of colony growth. Stable antibody-producing clones were then established by two sequential steps of single cell cloning.
Tissue Culture and Cell Lines
The IL-3-dependent mouse promyelomonocytic cell line FDC-P1 (4) was cultured in the high-glucose version of DMEM supplemented with 10% FCS, 50 µ M 2-mercaptoethanol, 13 µ M folic acid, 100 µ M L -asparagine and 1000 U/mL IL-3. The source of IL-3 was supernatant from X63/0 hybridoma cells stably transfected with an IL-3 expression construct (11) . Derivative clones of FDC-P1 cells transfected with a human bcl -2 expression construct, FDC-P1/Bcl-2 (10) or a human bcl -2 expression construct and a Glu-Glu (EE) epitope-tagged mouse bim L expression construct, FDC-P1/Bcl-2/EE-Bim L , have been described previously (16) .
Expression of Bim and Bcl-2 was verified by cytoplasmic immunofluorescent staining (see below and Reference 21) using 1 µ g/mL of the mouse anti-human Bcl-2 MAb Bcl-2-100 (17) or 2 µ g/mL mouse anti-EE MAb (anti-EE; BAbCO, Richmond, CA, USA). The secondary staining reagent was 5 µ g/mL fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG antibodies (Southern Biotechnology, Birmingham, AL, USA).
Hybridoma Screening
A 1:1 mixture of FDC-P1/Bcl-2 and FDC-P1/Bcl-2/EE Bim L cells was prepared and fixed in 1% paraformaldehyde for 15 min at room temperature. Cells were washed twice in balanced salt solution containing 2% FCS and 10 mM sodium azide (wash buffer), and 5 ×10 5 cells (in 100 µ L wash buffer) were dispensed into each well of 96-well soft plastic U-bottomed plates (Dynex Technologies, Chantilly, VA, USA). The cell pellets were resuspended in 100 µ L of day 10-11 hybridoma supernatant with 50 µ L of a 1% saponin solution (for cell permeabilization) in wash buffer, vortex mixed and incubated for 30 min on ice. Plates were washed twice by centrifugation for 3 min at 1500 rpm in a Sepatech Megafuge ® 1.0R (Heraeus Instruments, South Plainfield, NJ, USA) in wash buffer containing 0.03% saponin and resuspended in 100 µ L wash buffer containing 0.3% saponin and 10 µ g/mL FITC-coupled goat anti-rat IgG (heavyand light-chain reactive) antibodies (Southern Biotechnology) and incubated for 30 min on ice. Finally, cells were washed twice in wash buffer containing 0.03% saponin and resuspended in wash buffer. To confirm Bim L expression, a control sample was stained with mouse anti-EE antibodies (BabCO) and detected with 5 µ g/mL goat anti-mouse IgG antibodies conjugated to FITC (Southern Biotechnology). histograms were only printed from the positive samples. To speed up sample processing to a rate of 250-300 samples per hour, only 500 cells were analyzed. This allowed one person to screen 2000 hybridoma cultures in two days.
Expression Constructs and Protein Purification
The vectors pEF Bcl-2 pGKpuro , pEF FLAG ® Bim L and pEF EEBim L pGKhygrohave been described before (10, 16) . Full-length mouse bim L cDNA was cloned into pGEX (128/128) (Amersham Pharmacia Biotech; Reference 1) to allow production of GST-FLAGBim L protein in the bacterial strain JM109. The recombinant protein was purified from isopropyl β -D -thiogalactopyranoside (IPTG)-induced (Sigma Chemical, St Louis, MO, USA) bacterial cultures using binding to Glutathione-Sepharose 4B and elution with reduced glutathione (Amersham Pharmacia Biotech) (19) . The recombinant protein was resuspended in phosphatebuffered saline (PBS) pH 7.0.
Western Blotting
FDC-P1/Bcl-2 and FDC-P1/Bcl-2/EE Bim L cells were harvested in lysis buffer (20 mM Tris-HCl, pH 8.0, 125 mM NaCl, 1 mM EGTA, 1% Triton ® X-100, 10% glycerol, 1 µ g/mL each of leupeptin and aprotinin, 5 mM NaF and 2 mM Na 3 VO 4 [all from Sigma Chemical]; 0.5 µ g/mL Pefabloc ® , 1 µ g/mL of each soybean trypsin inhibitor and pepstatin [all from Boehringer Mannheim]). Lysates from 10 6 cells were boiled in gel running buffer (0.25 M Tris-HCl, pH 6.8, 1% sodium dodecyl sulfate [SDS], 20% glycerol, 5% 2-mercaptoethanol, 0.02% bromophenol blue), resolved on 4%-20% polyacrylamide gels (Novex, San Diego, CA, USA) and transferred to nitrocellulose membranes by electroblotting. After incubation overnight at 4°C in 5% skimmed milk, 1% casein and 0.05% Tween ® 20 to prevent nonspecific binding, the filters were incubated (1 h at room temperature) with the rat anti-Bim MAbs diluted 1:1 with blotting solution, followed by affinity-purified horseradish peroxidase (HRP)-conjugated goat anti-rat IgG antibodies (Southern Biotechnology). Proteins were visualized by enhanced chemiluminescence (ECL ™; Amersham Pharmacia Biotech, Little Chalfont, Bucks, England, UK).
Metabolic Labeling of Cells with [ 35 S]Methionine and Immunoprecipitation
Transient transfection of 293T human kidney embryonal cells with Bim expression constructs was as described (16 
RESULTS AND DISCUSSION
We wanted to produce monoclonal antibodies to Bim that could be used for immunofluorescence staining, immunohistochemistry, Western blotting and immunoprecipitation. Since immunization with peptide antigens and screening by ELISA often yield antibodies that cannot be used in these applications, we chose to screen hybridomas directly by immunofluorescence staining and flow cytometric analysis.
Since bimmRNA levels are low in cultured cell lines and in normal tissues (16) , it was impossible to use them for screening hybridomas. To overcome this, we used a transfected cell line stably expressing high levels of Bim. This was achieved by co-expressing Bcl-2 to block the pro-apoptotic activity of Bim (16) . The IL-3-dependent promyelomonocytic line FDC-P1 was transfected with a bcl -2/ puroexpression construct (10) and a construct encoding EE (Glu-Glu) epitope-tagged Bim L / hygro (16) . Clones expressing high levels of Bcl-2 and EE-Bim L were selected by continuous growth in the presence of both drugs and by immunofluorescent staining with monoclonal antibodies specific to Bcl-2 or the EE epitope tag ( Figure 1A ).
Rats were immunized with recombinant GST-Bim fusion protein. Hybridoma screening was performed 10-11 days after the fusion. The immunogen was tagged differently from the protein used for screening to avoid isolation of hybridomas producing tag-specific antibodies. A 1:1 ratio of FDC-P1/Bcl-2 and FDC-P1/Bcl-2/EE-Bim L cells were fixed, permeabilized with saponin and used to screen hybridoma supernatants. Those culture wells containing antibodies to Bim produced a double fluorescence peak when analyzed by flow cytometry (Figure 1, D-F) . The lower intensity peak represents background staining of FDC-P1/Bcl-2 cells. The higher fluorescence intensity peak is the result of specific Bim staining ( Figure 1A ). Culture supernatants with no Bim reactivity showed only a single peak of low fluorescence intensity ( Figure 1B) . Antibodies that were not specific to Bim but bound to some unknown epitope present in both FDC-P1/Bcl-2 and FDC-P1/Bcl-2/EE-Bim L cells produced a single peak with high fluorescence intensity ( Figure 1C) . Bim with high sensitivity and specificity (Figure 1, D-F) .
Epitope mapping of MAbs is possible with this technique, by using cell lines transfected with expression constructs encoding modified versions of the protein of interest. In the case of Bim, we used FDC-P1/Bcl-2 lines that co-express different isoforms or mutants of Bim and found that our MAbs detected only Bim L (data not shown).
Antibody isotyping could also be achieved by a simple adaptation of the staining protocol (Figure 2) . The mixture of FDC-P1/Bcl-2 cells and FDC-P1/Bcl-2/EE-Bim L cells was fixed, permeabilized and stained with each of the three anti-Bim antibodies. As a secondary reagent, we used biotinylated mouse anti-rat Ig isotype specific MAbs: anti-rat IgG1 (RG11/39.4), antirat IgG2a (RG7/1.30), anti-rat IgG2b (RG7/11.1) (20) and, in the final step, FITC-coupled streptavidin. To determine the Ig light chain isotype of the antibodies, we used FITC-coupled Mar 18.5 (13) mouse anti-rat Ig κ antibodies. This analysis demonstrated that the 4E4 and 5E5 antibodies are IgG2b/ κ , and the 9F5 antibody is IgG2a/ κ (Figure 2) .
We next investigated whether the three anti-Bim MAbs could be used for Western blotting (Figure 3 ) or immunoprecipitation (Figure 4 ). Bim could be detected in Western analysis by all three anti-Bim antibodies in lysates obtained from as few as 5 ×10 4 FDC-P1/Bcl-2/EE-Bim L cells when binding of the secondary antibody was revealed by ECL (Figure 3) . The three anti-Bim antibodies were also capable of immunoprecipitating Bim L protein from 293T cells that had been transiently transfected with a FLAGbim L expression construct (Figure 4 and data not shown). Both the Western blotting and immunoprecipitation assays clearly showed that the monoclonal anti-Bim antibodies were specific, as only Bim L was seen in FDC-P1/Bcl-2/EE-Bim L cells and no nonspecific protein was detected in FDC-P1/Bcl-2 cells.
Thus, the three Bim-specific MAbs obtained by using our novel flow cytometric screening system were also suitable for Western blot analysis, immunoprecipitation and immunohistochemical staining (unpublished). Antibody isotyping and epitope mapping were feasible using this technique. The screening system is rapid and has great potential for selecting highly specific MAbs to a range of low-abundance cytoplasmic proteins. Since the protein in the test cell line is stably expressed, it is likely that this approach selects for antibodies that recognize it in its native form. 3 and 5) were immunoprecipitated using the anti-FLAG antibody M2 (lanes 1  and 2) , the anti-Bim antibody 5E5 (lanes 3 and 4) or an isotype-matched control antibody to mouse CD4 (lanes 5 and 6). Both the anti-FLAG antibody and the anti-Bim 5E5 antibody immunoprecipitated a 23-kDa protein that corresponded with the expected mobility of FLAG-Bim L .
INTRODUCTION
Since the introduction of the solidphase, enzyme-linked immunospot (ELISPOT) (2,13), various adaptations have been introduced (3, 4, 10) . Czerkinsky et al. (2) first coined the term ELISPOT and immunohistochemically showed a spot-forming cell. Cell secretion of various cytokines [Interleukin (IL)-2, IL-4, IL-6, IL-10, interferon (IFN)-γ , tumor necrosis factor (TNF)-α and granulocyte-macrophage colony stimulating factor (GM-CSF)] can be detected by well-established protocols (5, 7, 10) . ELISPOT is simple to perform and correlates closely with the enzyme-linked immunosorbent assay (ELISA) technique (2, 3, 8) . However, unlike ELISA, in which the final quantification is done by a spectrophotome -
